No Data
No Data
10-Q: Q2 2024 Earnings Report
Express News | Nexalin Technology Announces Closing of $5.2 Million Public Offering
Express News | Nexalin Technology Announces Pricing of $5.2 Million Public Offering
Express News | Nexalin Technology Inc - No Serious Adverse Events Observed in Trial
Express News | Nexalin Technology: Study Shows Strong Statistical Separation Between Patients Receiving Nexalin's Difs Technology With Escitalopram Vs Sham Group
Express News | Nexalin Technology Announces Positive Clinical Study Data in Major Depressive Disorder and Publication of Clinical Trial Results in Leading Scientific Journal
No Data
No Data